JPI for Antimicrobial Resistance Research (AMR) launched an international call for projects! The call “Disrupting drug resistance using innovative design” will involve
26 funding organisations from 17 countries. The total estimated call budget is EURo 17 million.

This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.

Topic of the call:

Proposals should focus on licenced antimicrobial agents (antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should address at least one of the following topics:

• Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation);
• Drug/plant protection agent repurposing;
• Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines);
• Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials;
• Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.

Proposals can focus on one or more of the three “One-Health” settings, namely:

• Human Health, and/or
• Animal Health (including wildlife, livestock, fishes, and companion animals), and/or
• Plants (including trees and crops)

The following sub-topics are out of scope of the call:

• Antiviral and antiparasitic agents
• Discovery and/or screening of new compounds, new vaccines and/or new targets
• Proposals solely aiming to develop new diagnostics or new companion diagnostics (companion diagnostics in evaluation of the antimicrobials can be examined but they should not be the main topic of the proposal.)

Participation of end-users, stakeholders and companies is encouraged.

Hard Facts:

• Joint projects with a maximum of six – seven partners
• Maximum project duration of three years
• Max. EUR 300,000 funding per German applicant or max. EUR 500,000 German funding per project
• 08.03.2022 - Deadline for pre-proposal
• 05.07.2022 - Deadline for full-proposal

Participating Countries:

Belgium, Canada, Estonia, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Moldova, Poland, Spain, Sweden, Switzerland, United Kingdom

Further Information:

https://www.jpiamr.eu/calls/therapeutics-call-2022/

Contact at EPC:

© TU Dresden

Project Manager

Name

Mr Dr. Stefan Schuldt

ERA-Nets, BMBF Complementary measures

Send email

Send encrypted email via the SecureMail portal (for TUD external users only).

Contact Information

Organization Name

European Project Center

European Project Center

Address work

Visiting address:

FAL Falkenbrunnen BT-A Würzburger Straße 35

01187 Dresden

Show map of this location.

work Tel.